Paper42657179
Efficacy Analysis of Capsule Integrity and TACE Combined with Microwave Ablation versus Microwave Ablation Alone for Primary Hepatocellular Carcinoma.
Fang Y and 4 others. J Hepatocell Carcinoma, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Efficacy Analysis of Capsule Integrity and TACE Combined with Microwave Ablation versus Microwave Ablation Alone for Primary Hepatocellular Carcinoma. Papers, record 42657179. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42657179
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Efficacy Analysis of Capsule Integrity and TACE Combined with Microwave Ablation versus Microwave Ablation Alone for Primary Hepatocellular Carcinoma.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References23
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32965220 | TACE combined with microwave ablation therapy vs. TACE alone for treatment of early- and intermediate-stage hepatocellular carcinomas larger than 5 cm: a meta-analysis. | Diagn Interv Radiol | 2020 | https://conductscience.org/library/papers/32965220 | PubMed |
| 2 | 30676100 | Comparison of microwave ablation and radiofrequency ablation for hepatocellular carcinoma: a systematic review and meta-analysis. | Int J Hyperthermia | 2019 | https://conductscience.org/library/papers/30676100 | PubMed |
| 3 | 34570206 | Long-term Outcomes of Transcatheter Arterial Chemoembolization Combined With Radiofrequency Ablation as an Initial Treatment for Early-Stage Hepatocellular Carcinoma. | JAMA Netw Open | 2021 | https://conductscience.org/library/papers/34570206 | PubMed |
| 4 | 34007838 | Gene Polymorphism of MUC15, MMP14, BRAF, and COL1A1 Is Associated with Capsule Formation in Hepatocellular Carcinoma. | Can J Gastroenterol Hepatol | 2021 | https://conductscience.org/library/papers/34007838 | PubMed |
| 5 | 23269991 | Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. | J Clin Oncol | 2013 | https://conductscience.org/library/papers/23269991 | PubMed |
| 6 | 40785887 | Comparing the computed tomography radiologic features of cytokeratin 19-positive hepatocellular carcinoma to those of conventional hepatocellular carcinoma and intrahepatic cholangiocarcinoma. | Quant Imaging Med Surg | 2025 | https://conductscience.org/library/papers/40785887 | PubMed |
| 7 | 33442539 | Clinico-Radio-Pathological and Molecular Features of Hepatocellular Carcinomas with Keratin 19 Expression. | Liver Cancer | 2020 | https://conductscience.org/library/papers/33442539 | PubMed |
| 8 | 19533247 | Both fibrous capsule formation and extracapsular penetration are powerful predictors of poor survival in human hepatocellular carcinoma: a histological assessment of 365 patients in Japan. | Ann Surg Oncol | 2009 | https://conductscience.org/library/papers/19533247 | PubMed |
| 9 | 38572751 | Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | CA Cancer J Clin | 2024 | https://conductscience.org/library/papers/38572751 | PubMed |
| 10 | 25376296 | Hepatocellular carcinomas expressing 'stemness'-related markers: clinicopathological characteristics. | Dig Dis | 2014 | https://conductscience.org/library/papers/25376296 | PubMed |
| 11 | 37853415 | Deciphering intratumoral heterogeneity of hepatocellular carcinoma with microvascular invasion with radiogenomic analysis. | J Transl Med | 2023 | https://conductscience.org/library/papers/37853415 | PubMed |
| 12 | 39197823 | Local Ablation for Hepatocellular Carcinoma: 2024 Expert Consensus-Based Practical Recommendations of the Korean Liver Cancer Association. | Korean J Radiol | 2024 | https://conductscience.org/library/papers/39197823 | PubMed |
| 13 | 33578134 | The importance of a nonsmooth tumor margin and incomplete tumor capsule in predicting HCC microvascular invasion on preoperative imaging examination: a systematic review and meta-analysis. | Clin Imaging | 2021 | https://conductscience.org/library/papers/33578134 | PubMed |
| 14 | 39690085 | EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. | J Hepatol | 2025 | https://conductscience.org/library/papers/39690085 | PubMed |
| 15 | 39691767 | Intelligent Hydrogel-Assisted Hepatocellular Carcinoma Therapy. | Research (Wash D C) | 2024 | https://conductscience.org/library/papers/39691767 | PubMed |
| 16 | 39176099 | Multi-transcriptomics analysis of microvascular invasion-related malignant cells and development of a machine learning-based prognostic model in hepatocellular carcinoma. | Front Immunol | 2024 | https://conductscience.org/library/papers/39176099 | PubMed |
| 17 | 37199193 | AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. | Hepatology | 2023 | https://conductscience.org/library/papers/37199193 | PubMed |
| 18 | 18769333 | Extracapsular penetration is a new prognostic factor in human hepatocellular carcinoma. | Am J Surg Pathol | 2008 | https://conductscience.org/library/papers/18769333 | PubMed |
| 19 | 26365503 | Radiofrequency ablation versus surgical resection for hepatocellular carcinoma within the Milan criteria: A study of 281 Western patients. | Int J Hyperthermia | 2015 | https://conductscience.org/library/papers/26365503 | PubMed |
| 20 | 41112038 | RRM2-targeted nanocarrier enhances radiofrequency ablation efficacy in hepatocellular carcinoma through ferroptosis amplification and immune remodeling. | Imeta | 2025 | https://conductscience.org/library/papers/41112038 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42657179
GET https://conductscience.org/api/papers/v1/42657179/references?page=2